RxDoctor Payments Data

Paul Fidrych

Nurse Practitioner · Norwich, CTNPI 1972121630

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.4% of the total across 950 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 57 manufacturers, the largest accounting for just 21.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $6,537, 4.0 times the $1,629 reported in 2021. Among nurse practitioner clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$23,298in general payments, 2019–2025

Across 950 payments — averaging $24.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • EMD Serono, Inc.$3K
  • Novartis$2K
  • Pfizer$1K
  • Eisai Inc.$983
  • Biogen$892
  • plus $10K from 51 others

What the payments were for

  • Consulting fees$5252%
  • Food & beverage$22,68897%
  • Education$850%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)224$4,974
EMD Serono, Inc.89$3,379
Novartis79$2,067
Pfizer72$1,438
Eisai Inc.22$983
Biogen42$892
TG Therapeutics, Inc.25$879
Lundbeck LLC31$834
UCB, Inc.30$785
Amgen(2 entities)27$583
SK Life Science, Inc.20$453
Octapharma USA, Inc.9$451
Bristol Myers Squibb23$434
Amneal Pharmaceuticals LLC21$423
Teva Pharmaceuticals USA, Inc.23$397
AstraZeneca(2 entities)21$381
Johnson & Johnson(2 entities)15$358
Lilly USA, LLC14$248
CSL Behring12$238
Otsuka America Pharmaceutical, Inc.8$225
Biohaven Pharmaceutical Holding Company Ltd.10$222
Scilex Pharmaceuticals Inc.10$218
Sanofi11$210
Genentech USA, Inc.9$191
Takeda Pharmaceuticals U.S.A., Inc.9$171
Sunovion Pharmaceuticals Inc.9$134
Mallinckrodt Hospital Products Inc.6$122
Axsome Therapeutics, Inc.5$116
Vanda Pharmaceuticals Inc.5$111
Cycle Pharmaceuticals Inc3$111
E.r. Squibb & Sons, L.L.C.1$89
Avanir Pharmaceuticals, Inc.4$88
Argenx US, Inc.3$76
Upsher-smith Laboratories LLC5$75
Tanabe Pharma America, Inc.4$75
Kyowa Kirin, Inc.4$73
Neurocrine Biosciences, Inc.3$63
GE HealthCare2$57
Ipsen Biopharmaceuticals, Inc3$51
Alnylam Pharmaceuticals Inc.3$50
Azurity Pharmaceuticals, Inc.3$47
Averitas Pharma Inc.2$45
Collegium Pharmaceutical, Inc.2$44
MDD US Operations, LLC2$44
Impel Pharmaceuticals Inc.3$43
Tonix Medicines, Inc.2$39
Kedrion Biopharma, Inc.2$39
Sumitomo Pharma America, Inc.4$39
Amylyx Pharmaceuticals, Inc.2$37
Life Molecular Imaging Ltd3$35
Merz Pharmaceuticals, LLC2$32
Currax Pharmaceuticals LLC2$28
ANI Pharmaceuticals, Inc.1$25
Supernus Pharmaceuticals, Inc.1$25
Almatica Pharma LLC1$20
Grifols USA, LLC1$16
Biohaven Pharmaceuticals, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,298 in reported general payments places this provider in the 95th percentile of 1,162 nurse practitioner providers in Connecticut.

See all nurse practitioner providers in Connecticut

Medicare billing

Part B allowed, 2024
$38,279
Medicare patients
206
Services billed
1,301

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate116$193,408
UbrelvyUbrogepant113$179,212
QuliptaAtogepant65$104,637
Aimovig AutoinjectorErenumab-Aooe42$39,464
Emgality PenGalcanezumab-Gnlm38$26,351
Memantine Hcl202$5,475
Gabapentin211$5,458
Rivastigmine25$4,788
Carbamazepine ErCarbamazepine38$4,284
Oxcarbazepine32$3,616
Donepezil Hcl237$2,601
Carbidopa-LevodopaCarbidopa/Levodopa112$2,277
Levetiracetam42$1,430
Propranolol Hcl ErPropranolol Hcl46$1,335
Lamotrigine59$1,312

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$4,974$283,849178 claims
PfizerNurtec Odt$1,438$193,408116 claims
Upsher-smith Laboratories LLCTopiramate$75$43747 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,162 nurse practitioner providers in Connecticut.

Other nurse practitioner in Norwich

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →